HRP20041238A2 - Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation - Google Patents

Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation

Info

Publication number: HRP20041238A2
Authority: HR; Croatia
Prior art keywords: redught; hyaluronic acid; hmg coa; cetp inhibitors; acid formulation
Prior art date: 2002-07-02

Application number

HR20041238A

Other languages

English (en)

Inventor

Trung Nguyen Tu

Lester Shear Charles

Harold Revkin James

Benjamin Ruggeri Roger

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-02

Filing date

2004-12-30

Publication date

2005-06-30

2004-12-30 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-06-30 Publication of HRP20041238A2 publication Critical patent/HRP20041238A2/xx

Links

KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title 1
239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
238000009472 formulation Methods 0.000 title 1
229920002674 hyaluronan Polymers 0.000 title 1
229960003160 hyaluronic acid Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Biochemistry (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)

HR20041238A 2002-07-02 2004-12-30 Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation HRP20041238A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39339502P	2002-07-02	2002-07-02
PCT/IB2003/002792 WO2004004778A1 (fr)	2002-07-02	2003-06-18	Utilisation d'inhibiteurs cetp et eventuellement d'inhibiteurs de la hmg coa reductase et/ou d'agents anti-hypertensifs

Publications (1)

Publication Number	Publication Date
HRP20041238A2 true HRP20041238A2 (en)	2005-06-30

Family

ID=30115572

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20041238A HRP20041238A2 (en)	2002-07-02	2004-12-30	Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation

Country Status (23)

Country	Link
US (1)	US20040053842A1 (fr)
EP (1)	EP1519754A1 (fr)
JP (1)	JP2005532388A (fr)
KR (1)	KR20050025578A (fr)
CN (1)	CN1665537A (fr)
AP (1)	AP2004003189A0 (fr)
AU (1)	AU2003244921A1 (fr)
BR (1)	BR0312421A (fr)
CA (1)	CA2488736A1 (fr)
EA (1)	EA200401471A1 (fr)
EC (1)	ECSP045520A (fr)
HR (1)	HRP20041238A2 (fr)
IL (1)	IL165328A0 (fr)
IS (1)	IS7570A (fr)
MA (1)	MA27311A1 (fr)
MX (1)	MXPA05000015A (fr)
NO (1)	NO20050497L (fr)
OA (1)	OA12876A (fr)
PL (1)	PL374878A1 (fr)
TN (1)	TNSN04268A1 (fr)
TW (1)	TW200401768A (fr)
WO (1)	WO2004004778A1 (fr)
ZA (1)	ZA200409582B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
ATE389396T1 (de) *	2002-12-20	2008-04-15	Pfizer Prod Inc	Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
DE60331873D1 (de) *	2002-12-20	2010-05-06	Pfizer Prod Inc	Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2004205642C1 (en)	2003-01-14	2012-01-12	Arena Pharmaceuticals, Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
KR100857759B1 (ko) *	2003-03-17	2008-09-09	니뽄 다바코 산교 가부시키가이샤	Ｃｅｔｐ 억제제의 약제학적 조성물
BRPI0408442A (pt) *	2003-03-17	2006-04-04	Japan Tobacco Inc	método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
TWI393560B (zh) *	2003-05-02	2013-04-21	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
EP2319843B1 (fr) *	2003-05-30	2013-04-03	Ranbaxy Laboratories Limited	Derivés de pyrrole subsitués et leur utilisation comme inhibiteurs de HMG-CO
BRPI0412689A (pt)	2003-07-14	2006-10-03	Arena Pharm Inc	derivados de heteroarila e arila fundida como moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a ele
AU2004298351A1 (en) *	2003-12-16	2005-06-30	Novartis Ag	Use of stating for the treatment of metabolic syndrome
KR20070002085A (ko) *	2004-04-07	2007-01-04	밀레니엄 파머슈티컬스 인코퍼레이티드	염증 질병을 치료하기 위한 ｐｇｄ２ 수용체 길항제
US20060063803A1 (en) *	2004-09-23	2006-03-23	Pfizer Inc	4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2006054308A2 (fr) *	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Formulations d'atorvastatine stables
CA2587791C (fr)	2004-12-06	2012-03-13	Avigen, Inc.	Methode de traitement des douleurs neuropathiques et les syndromes associes
US7700774B2 (en) *	2004-12-20	2010-04-20	Dr. Reddy's Laboratories Ltd.	Heterocyclic compounds and their pharmaceutical compositions
EP1833466A1 (fr) *	2004-12-28	2007-09-19	Ranbaxy Laboratories Limited	Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine
CA2605214C (fr)	2004-12-31	2016-07-12	Reddy Us Therapeutics, Inc.	Nouveaux derives de benzylamine en tant qu'inhibiteurs de cetp
US8604055B2 (en) *	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MY148521A (en)	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007106111A2 (fr) *	2005-07-01	2007-09-20	Elan Pharma International Limited	Compositions nanoparticulaires et a liberation controlee comprenant de la nilvadipine
EP1948600B1 (fr)	2005-07-05	2014-04-16	The President & Fellows Of Harvard College	Conjugues cibles sur le foie
JP2009514851A (ja) *	2005-11-08	2009-04-09	ランバクシーラボラトリーズリミテッド	（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
WO2008020314A2 (fr) *	2006-03-14	2008-02-21	Ranbaxy Laboratories Limited	Formulations de dosage stabilisantes à base de statine
WO2007115132A2 (fr) *	2006-03-29	2007-10-11	Guilford F Timothy	Produit radiopharmaceutique utilisé dans une préparation liposomale auto-formante pouvant être administrée par diverses voies, contenant d'autres ingrédients
WO2007116243A2 (fr) *	2006-04-10	2007-10-18	Mintails Limited	Procede de traitement de la fibromyalgie et de pathologies apparentees
BRPI0714361A2 (pt) *	2006-07-14	2013-03-26	Ranbaxy Lab Ltd	polimorfo cristalino, composiÇço farmacÊutica contendo o mesmo, mÉtodo para sua preparaÇço e mÉtodo de tratamento
DK2131841T3 (da) *	2007-01-30	2012-10-15	Avigen Inc	Fremgangsmåder til behandling af akut smerte
WO2008137012A1 (fr) *	2007-05-03	2008-11-13	Avigen, Inc.	Utilisation d'un atténuateur glial destiné à prévenir des réponses de douleurs amplifiées provoquées par un amorçage glial
EP2158333A4 (fr) *	2007-05-14	2010-12-29	Synvista Therapeutics Inc	Utilisation du génotypage de l'haptoglobine pour le diagnostic et le traitement pour le transport inverse défectueux du cholestérol (rct)
WO2009021113A1 (fr) *	2007-08-09	2009-02-12	Holtzman, Jordan, L.	Procédés de stimulation de l'activité de la glutathion peroxydase
EP2070520A1 (fr)	2007-12-11	2009-06-17	LEK Pharmaceuticals D.D.	Composition pharmaceutique comportant au moins un agent actif et un liant, qui gonfle dans un support acide
CA2812061A1 (fr)	2010-09-22	2012-03-29	Arena Pharmaceuticals, Inc.	Modulateurs du recepteur gpr119 et traitement des troubles qui lui sont lies
EP2626351A4 (fr) *	2010-10-04	2014-03-12	Kowa Co	Agent capable d'inhiber l'expression d'un arnm lié au métabolisme lipidique
JP5964965B2 (ja)	2011-08-18	2016-08-03	ドクターレディズラボラトリーズリミテッド	コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (fr)	2011-09-27	2015-06-19	Reddys Lab Ltd Dr
MA40590A (fr) *	2014-08-28	2017-07-05	Dezima Pharma B V	Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase
WO2016112075A1 (fr)	2015-01-06	2016-07-14	Arena Pharmaceuticals, Inc.	Procédés de traitement de maladies associées au récepteur s1p1
AU2016284162A1 (en)	2015-06-22	2018-02-01	Arena Pharmaceuticals, Inc.	Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
WO2018019911A1 (fr) *	2016-07-27	2018-02-01	Hartis-Pharma Sarl	Combinaisons thérapeutiques pour traiter les troubles des globules rouges
WO2018151873A1 (fr)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN116196314B (zh) *	2023-05-04	2023-08-15	广州市妇女儿童医疗中心	Ri-1或其盐在制备防治胃肠道疾病的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6144790A (en) *	1997-02-07	2000-11-07	Bledin; Anthony G	Contact fiber optic impact sensor
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.
CA2296726C (fr) *	1997-08-29	2004-06-29	Pfizer Products Inc.	Therapie combinee
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) *	1998-09-17	2000-10-31	Pfizer Inc.	Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
PL353483A1 (en) *	1999-05-27	2003-11-17	Pfizer Products Inc.	Mutual prodrugs of amlodipine and atorvastatin
HN2000000050A (es) *	1999-05-27	2001-02-02	Pfizer Prod Inc	Sal mutua de amlodipino y atorvastatina
US20030092745A1 (en) *	2000-02-25	2003-05-15	Pfizer Inc.	Combination therapy
US20020013334A1 (en) *	2000-06-15	2002-01-31	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method
MXPA03001419A (es) *	2000-08-15	2003-06-06	Pfizer Prod Inc	Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
US6737430B2 (en) *	2000-11-09	2004-05-18	Pfizer, Inc.	Mutual prodrug of amlodipine and atorvastatin
CA2444429A1 (fr) *	2001-04-11	2002-11-07	Atherogenics, Inc.	Procedes d'accroissement des taux de cholesterol hdl du plasma et d'amelioration de la fonctionnalite hdl avec des monoesters de probucol
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof

2003
- 2003-06-10 US US10/459,683 patent/US20040053842A1/en not_active Abandoned
- 2003-06-18 EP EP03738394A patent/EP1519754A1/fr not_active Withdrawn
- 2003-06-18 KR KR1020057000061A patent/KR20050025578A/ko not_active Application Discontinuation
- 2003-06-18 BR BR0312421-5A patent/BR0312421A/pt not_active IP Right Cessation
- 2003-06-18 CA CA002488736A patent/CA2488736A1/fr not_active Abandoned
- 2003-06-18 EA EA200401471A patent/EA200401471A1/ru unknown
- 2003-06-18 IL IL16532803A patent/IL165328A0/xx unknown
- 2003-06-18 CN CN038155753A patent/CN1665537A/zh active Pending
- 2003-06-18 AU AU2003244921A patent/AU2003244921A1/en not_active Abandoned
- 2003-06-18 JP JP2004519080A patent/JP2005532388A/ja not_active Withdrawn
- 2003-06-18 AP AP2004003189A patent/AP2004003189A0/xx unknown
- 2003-06-18 OA OA1200400342A patent/OA12876A/en unknown
- 2003-06-18 WO PCT/IB2003/002792 patent/WO2004004778A1/fr not_active Application Discontinuation
- 2003-06-18 MX MXPA05000015A patent/MXPA05000015A/es not_active Application Discontinuation
- 2003-06-18 PL PL03374878A patent/PL374878A1/xx not_active Application Discontinuation
- 2003-07-01 TW TW092117985A patent/TW200401768A/zh unknown
2004
- 2004-11-26 ZA ZA200409582A patent/ZA200409582B/en unknown
- 2004-11-29 IS IS7570A patent/IS7570A/is unknown
- 2004-12-17 MA MA28016A patent/MA27311A1/fr unknown
- 2004-12-30 HR HR20041238A patent/HRP20041238A2/xx not_active Application Discontinuation
- 2004-12-30 EC EC2004005520A patent/ECSP045520A/es unknown
- 2004-12-30 TN TNP2004000268A patent/TNSN04268A1/fr unknown
2005
- 2005-01-28 NO NO20050497A patent/NO20050497L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IS7570A (is)	2004-11-29
IL165328A0 (en)	2006-01-15
EA200401471A1 (ru)	2005-06-30
AP2004003189A0 (en)	2004-12-31
TNSN04268A1 (fr)	2007-03-12
WO2004004778A1 (fr)	2004-01-15
EP1519754A1 (fr)	2005-04-06
MXPA05000015A (es)	2005-04-08
TW200401768A (en)	2004-02-01
ZA200409582B (en)	2006-08-30
CN1665537A (zh)	2005-09-07
US20040053842A1 (en)	2004-03-18
OA12876A (en)	2006-09-15
ECSP045520A (es)	2005-03-10
CA2488736A1 (fr)	2004-01-15
NO20050497L (no)	2005-03-08
PL374878A1 (en)	2005-11-14
MA27311A1 (fr)	2005-05-02
KR20050025578A (ko)	2005-03-14
JP2005532388A (ja)	2005-10-27
AU2003244921A1 (en)	2004-01-23
BR0312421A (pt)	2005-04-19

Publication	Publication Date	Title
HRP20041238A2 (en)	2005-06-30	Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation
IL165910A0 (en)	2006-01-15	Compositions of hyaluronic acid and methods of use
PL374364A1 (en)	2005-10-17	Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors
AU2003303128A8 (en)	2004-08-13	Inhibitors and methods of use thereof
AU2003288126A1 (en)	2004-06-18	Anthranilic acid amides and the derivatives thereof as cosmetic and pharmaceutical agents
IL145346A0 (en)	2002-06-30	Dimeric compounds and their use as inhibitors of neuraminidase
EP1507756A4 (fr)	2006-03-15	Inhibiteurs de ccr9 et utilisation de ceux-ci
AU2003217870A8 (en)	2003-09-16	Pini-modulating compounds and methods of use thereof
ZA200500680B (en)	2006-08-30	Quinoline derivatives and their use as mycrobacterial inhibitors
IL161134A0 (en)	2004-08-31	Ester compound and medical use thereof
AU2003213673A8 (en)	2003-09-16	Pin1-modulating compounds and methods of use thereof
AU2003278832A8 (en)	2004-04-30	Optical biosensors and methods of use thereof
EP1549614A4 (fr)	2008-04-16	Agents vasculo-statiques et procedes d'utilisation de ceux-ci
AU2003225669A1 (en)	2004-04-19	Pin1-modulating compounds and methods of use thereof
AU2003225668A1 (en)	2003-09-16	Pin1-modulating compounds and methods of use thereof
EP1448218A4 (fr)	2009-01-14	Inhibiteurs de la beta-secretase et leurs procede d'utilisation
IL205407A0 (en)	2011-07-31	Hyaluronic acid antagonist and inhibitor compositions and uses thereof
EP1476150A4 (fr)	2007-07-04	Carboxyfullerenes et procedes d'utilisation de ceux-ci
EP1487776A4 (fr)	2005-05-25	Composes acides et esters et procedes d'utilisation associes
PL374581A1 (en)	2005-10-31	Diaminothiazoles and use thereof as cdk4 inhibitors
AU2003215364A1 (en)	2003-09-09	Carboxylic acid containing protective coating compositions and methods of use thereof
EP1503749A4 (fr)	2008-04-09	Inhibiteurs de methionine aminopeptidase-2 et procedes d'utilisation de ceux-ci
AU2002337913A1 (en)	2003-04-28	Glycosulfopeptide inhibitors and methods of use thereof
AU2003205570A1 (en)	2003-07-24	Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
IL163959A (en)	2010-12-30	Derivatives of phenyl-sulfonylamino- benzoic acid and pharmaceutical compositions comprising them

Legal Events

Date	Code	Title	Description
2005-06-30	A1OB	Publication of a patent application
2005-12-19	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2006-06-08	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20060608 Year of fee payment: 4
2008-11-06	OBST	Application withdrawn